DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Intranasal Capsaicin Treatment for Non-Allergic Irritant Rhinitis

Information source: The University of Texas Health Science Center, Houston
ClinicalTrials.gov processed this data on August 20, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Nonallergic Irritant Rhinitis

Intervention: Capsaicin (Drug); Placebo (Drug)

Phase: Phase 2

Status: Recruiting

Sponsored by: The University of Texas Health Science Center, Houston

Official(s) and/or principal investigator(s):
Chauchau T Pham, MD, MS, Principal Investigator, Affiliation: The University of Texas Health Science Center, Houston

Overall contact:
Chauchau T Pham, MD, MS, Email: chauchau.t.pham@uth.tmc.edu

Summary

The proposed study seeks to investigate the effect of intranasal capsaicin treatment in patient with Non-allergic irritant rhinitis (NAIR), as well as evaluate optical rhinometry (ORM) as a means to quantify symptomatic improvement in NAIR patients during and after treatment.

Clinical Details

Official title: Double-Blinded Randomized Prospective Trial of Intranasal Capsaicin Treatment for Non-Allergic Irritant Rhinitis

Study design: Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Primary outcome:

Change in Composite Symptom Scores at 4 weeks

Change in Composite Symptom Scores at 12 weeks

Change at 4 weeks in maximum optical density with intranasal capsaicin challenge

Change at 12 weeks in maximum optical density with intranasal capsaicin challenge

Detailed description: A study by Lambert et. al. (2012) was able to objectively identify patients with NAIR by intranasal capsaicin challenge followed by assessment with optical rhinometry. Studies have shown that capsaicin therapy can improve symptoms of patients historically identified with NAIR via visual analog scale (VAS) rating of symptoms and symptom surveys; however, there has been no study evaluating the capsaicin therapy on patients objectively identified as NAIR patients. Multiple studies have demonstrated that intranasal capsaicin can improve nasal symptoms of NAIR patients. Regarding the usage of capsaicin, there is a product on the market: Sinus Buster which has capsaicin as the active ingredient. Numerous research papers have evaluated the efficacy and safety of Sinus Buster for the treatment of congestion in non-allergic rhinitis patients. However, the diagnosis of NAIR in these previous studies was based primarily on history. In addition, the primary outcome in these studies was symptomatic without any objective evaluation. The goal of this study will be two-fold: with patients objectively identified as NAIR patients via the optical rhinometer, we will re-evaluate the therapeutic action of intranasal capsaicin on the management of rhinitic symptoms. We expect that the patients will show significant improvement in their symptoms. We will then use optical rhinometry as a means to objectively monitor changes in symptoms in NAIR patients. We expect that post treatment, patients will no longer have the positive response previously seen on intranasal capsaicin challenge before receiving treatment. We hope to be able to establish optical rhinometry as an objective measurement of symptom improvement for NAIR symptoms, along with the subjective patient surveys.

Eligibility

Minimum age: 18 Years. Maximum age: 65 Years. Gender(s): Both.

Criteria:

Inclusion criteria:

- Non-allergic irritant rhinitis (NAIR) patients as defined by history (symptoms of

nasal congestion, rhinorrhea, nasal itching or sneezing upon exposure to nasal irritants)

- Patients with positive optical rhinometer (ORM) response with intranasal challenge

with 0. 5 mM capsaicin as described by Lambert et al 2012

- Between 18-65 years of age

- Confirmed negative skin prick test to common allergens (which rules out allergic

rhinitis) Exclusion Criteria:

- History of sinonasal surgery

- Chronic rhinosinusitis

- Inflammatory or granulomatous diseases

- Asthma

- Allergic rhinitis

- Immunocompromised state

- Radiation to the head and neck

- Intranasal steroid use >4 wks

- Intranasal or systemic antihistamine x 3 days

- Intranasal or systemic decongestants x 3 days

Locations and Contacts

Chauchau T Pham, MD, MS, Email: chauchau.t.pham@uth.tmc.edu

The University of Texas Health Science Center at Houston, Houston, Texas 77030, United States; Recruiting
Chauchau T Pham, MD, MS, Email: chauchau.t.pham@uth.tmc.edu
Chauchau T Pham, MD, MS, Principal Investigator
Additional Information

Starting date: October 2014
Last updated: July 6, 2015

Page last updated: August 20, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017